Delivery Order SPE2DB24D9144-SPE2DB25FCNBC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order for delivery to Park Ridge, IL. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 4, 2025, and no set-aside designation...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $39,898 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40mg capsules (120 count). This firm fixed-price delivery order, issued September 13, 2025, represents a direct procurement requiring fulfillment at the vendor's facility in Park Ridge, Illinois. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a woman-owned...
- The Defense Logistics Agency awarded a $4.3K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). The contract, issued as a firm fixed-price delivery order on September 9, 2025, with completion scheduled for September 10, 2025, represents a single pharmaceutical product delivery supporting Department of Defense healthcare operations. This award carries no...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- The U.S. Defense Department's Medical Supply Chain division awarded a delivery order valued at $34,490.80 to DMS Pharmaceutical Group Inc. on August 28, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with a firm fixed-price arrangement and an ultimate completion date of August 29, 2025. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCNBCDelivery Order
The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The award, issued on September 26, 2025, with an ultimate completion date of September 29, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products supporting military health facilities worldwide. DMS Pharmaceutical Group leverages its established position as a critical supplier in the federal pharmaceutical supply chain to fulfill this oncology medication requirement for Department of Defense healthcare sites. The company's extensive portfolio of federal contracts demonstrates consistent success in delivering prescription medications, biologics, and medical consumables to military facilities nationwide. Xtandi, a hormone therapy treatment, represents the type of specialized pharmaceutical product that DMS Pharmaceutical Group routinely supplies through its DLA contract vehicle, reinforcing its role as a key distributor of branded prescription drugs to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/26/25 |